CEL-SCI Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

CEL-SCI has a total shareholder equity of $8.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $24.1M and $15.6M respectively.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$435.78k
Eşitlik	US$8.47m
Toplam yükümlülükler	US$15.60m
Toplam varlıklar	US$24.07m

Son finansal sağlık güncellemeleri

We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

Mar 01

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CVM's short term assets ($3.5M) do not cover its short term liabilities ($5.5M).

Uzun Vadeli Yükümlülükler: CVM's short term assets ($3.5M) do not cover its long term liabilities ($10.1M).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CVM is debt free.

Borcun Azaltılması: CVM had no debt 5 years ago.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CVM has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Tahmini Nakit Akışı: CVM is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.

CEL-SCI Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

Recent updates

CEL-SCI Corporation Reports New Data from Its Concluded Phase 3 Study of Multikine® (Leukocyte Interleukin, Injection)

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI Corporation A Pediatric Waiver, Bringing Multikine One Step Closer to Future Marketing Clearance

CEL-SCI Corporation has completed a Follow-on Equity Offering in the amount of $10.7737 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $10.845 million.

CEL-SCI Corporation Announces Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer

CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board

CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index

New major risk - Financial position

CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine

Less than half of directors are independent

No longer forecast to breakeven

New minor risk - Market cap size

CEL-SCI Corporation, Annual General Meeting, Apr 19, 2024

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $7.75 million.

CEL-SCI Corporation has completed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-Sci Corporation Releases Video Detailing Recent Phase 3 Findings & Its Plans to Seek Immediate Regulatory Approvals

CEL-SCI Presents the Data for the First Time at the European Society for Medical Oncology Congress in Spain

New major risk - Share price stability

Cel-Sci Files Request with the Uk's Mhra Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer

Cel-Sci Submits Scientific Advice Filing to European Medicines Agency (Ema) for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Corporation Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination with Checkpoint Inhibitors for Head & Neck Cancer

New minor risk - Market cap size

CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed

CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed

CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikine

No longer forecast to breakeven

Forecast breakeven date moved forward to 2023

Price target decreased by 23% to US$11.50

Consensus revenue estimates fall by 33%

Forecast breakeven date pushed back to 2024

Price target increased to US$15.00

Forecast breakeven date pushed back to 2024

CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results

CEL-SCI Corporation Appoints Gail Naughton to its Board of Directors

CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Growth Index

CEL-SCI Corporation, Annual General Meeting, Jun 13, 2022

Price target increased to US$15.00

Insufficient new directors

Chief Scientific Officer recently sold US$169k worth of stock

Price target decreased to US$12.00

Forecast breakeven pushed back to 2023

Market Sentiment Around Loss-Making CEL-SCI Corporation (NYSEMKT:CVM)

Insider recently sold US$244k worth of stock

We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

New 90-day high: US$26.54

What Does CEL-SCI's (NYSEMKT:CVM) CEO Pay Reveal?

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$0.82 loss per share

Breakeven On The Horizon For CEL-SCI Corporation (NYSEMKT:CVM)

CEL-SCI’s LEAPS Peptides Demonstrate Clear Survival Benefit as A Treatment for COVID-19 in Preclinical Studies

Insider notifies of intention to sell stock

Insider recently sold US$127k worth of stock

New 90-day low: US$11.56

New 90-day high: US$14.51

Analysts update estimates

Third quarter earnings released

New 90-day low - US$12.04

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin